Integrative analysis of RUNX1 downstream pathways and target genes.

Détails

Ressource 1Télécharger: BIB_4D757BDF83EB.P001.pdf (1509.54 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_4D757BDF83EB
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Integrative analysis of RUNX1 downstream pathways and target genes.
Périodique
BMC Genomics
Auteur⸱e⸱s
Michaud J., Simpson K.M., Escher R., Buchet-Poyau K., Beissbarth T., Carmichael C., Ritchie M.E., Schütz F., Cannon P., Liu M., Shen X., Ito Y., Raskind W.H., Horwitz M.S., Osato M., Turner D.R., Speed T.P., Kavallaris M., Smyth G.K., Scott H.S.
ISSN
1471-2164 (Electronic)
ISSN-L
1471-2164
Statut éditorial
Publié
Date de publication
2008
Volume
9
Numéro
363
Pages
363
Langue
anglais
Résumé
BACKGROUND: The RUNX1 transcription factor gene is frequently mutated in sporadic myeloid and lymphoid leukemia through translocation, point mutation or amplification. It is also responsible for a familial platelet disorder with predisposition to acute myeloid leukemia (FPD-AML). The disruption of the largely unknown biological pathways controlled by RUNX1 is likely to be responsible for the development of leukemia. We have used multiple microarray platforms and bioinformatic techniques to help identify these biological pathways to aid in the understanding of why RUNX1 mutations lead to leukemia. RESULTS: Here we report genes regulated either directly or indirectly by RUNX1 based on the study of gene expression profiles generated from 3 different human and mouse platforms. The platforms used were global gene expression profiling of: 1) cell lines with RUNX1 mutations from FPD-AML patients, 2) over-expression of RUNX1 and CBFbeta, and 3) Runx1 knockout mouse embryos using either cDNA or Affymetrix microarrays. We observe that our datasets (lists of differentially expressed genes) significantly correlate with published microarray data from sporadic AML patients with mutations in either RUNX1 or its cofactor, CBFbeta. A number of biological processes were identified among the differentially expressed genes and functional assays suggest that heterozygous RUNX1 point mutations in patients with FPD-AML impair cell proliferation, microtubule dynamics and possibly genetic stability. In addition, analysis of the regulatory regions of the differentially expressed genes has for the first time systematically identified numerous potential novel RUNX1 target genes. CONCLUSION: This work is the first large-scale study attempting to identify the genetic networks regulated by RUNX1, a master regulator in the development of the hematopoietic system and leukemia. The biological pathways and target genes controlled by RUNX1 will have considerable importance in disease progression in both familial and sporadic leukemia as well as therapeutic implications
Mots-clé
Animals, Blood Platelet Disorders/genetics, Cell Line, Transformed, Computational Biology, Core Binding Factor Alpha 2 Subunit/genetics, Core Binding Factor beta Subunit/genetics, Gene Expression Profiling/methods, Gene Expression Regulation, Gene Regulatory Networks, Genetic Predisposition to Disease, Hela Cells, Humans, Leukemia, Myeloid, Acute/genetics, Mice, Mice, Inbred BALB C, Oligonucleotide Array Sequence Analysis, Point Mutation
Pubmed
Web of science
Open Access
Oui
Création de la notice
29/01/2009 22:14
Dernière modification de la notice
20/08/2019 14:02
Données d'usage